肝内胆管癌患者血清CXCL9和IFN-γ水平变化及其临床意义探讨

doi:10.3969/j.issn.1672-5069.2021.05.034

Abstract

Abstract: Objective The purpose of this study was to investigate the clinical implication of serum C-X-C chemokine ligand 9 (CXCL9) and interferon-γ (IFN-γ) levels in patients with intrahepatic cholangiocarcinoma (ICC). Methods A total of 63 patients with ICC and 63 healthy persons were enrolled in our hospital between January 2012 and January 2017, and all patients underwent radical tumor removal and followed-up for 36 months. Serum levels of CXCL9 and IFN-γ were detected by enzyme-linked immunosorbent assay. The Kaplan-Meier survival curve was applied to analyze serum CXCL9 and IFN-γ levels in predicting the prognosis of patients with ICC after operation. Results Serum CXCL9 and IFN-γ levels in patients with ICC were (820.7±185.6)pg/mL and (18.7±7.2)ng/L, significantly different as compared to or in healthy persons; there were significant differences as respect to serum CXCL9 and IFN-γ levels between ICC patients with TNM stage Ⅰ/Ⅱ vs. stage Ⅲ/Ⅳ, with or without lymph node metastasis, and poorly vs. moderately/highly differentiated tumors(P<0.05); at the end of 36 month follow-up, 42 (66.7%) patients with ICC died and 21 (33.3%)patients survived in our series; 30 patients with ICC had low and 33 had high serum CXCL9 levels when 820.7 pg/mL was set as the cut-off-value, and the Kaplan-Meier analysis showed that the 36_mon survival in patients with low serum CXCL9 levels was 53.3%, significantly higher than 15.2%(x²=12.448, P<0.001)in patients with high serumCXCL9 levels; 34 ICC patients had low and 29 patients had high serum IFN-γ levels when 18.7 ng/L was set as the cut-off-value, and the 36_mon survival in patients with low serum IFN-γ levels was 14.7%, significantly lower than 55.2%(x²=10.554,P=0.001) in patients with high serum IFN-γ levels. Conclusion Serum CXCL9 levels increase and serum IFN-γ levels decrease in patients with ICC, and serum CXCL9 and IFN-γ levels are correlated with the prognosis of ICC patients after radical operation. The surveillance of serum CXCL9 and IFN-γ levels in this setting is helpful to evaluate the prognosis of patients with ICC.

Key words: Intrahepatic cholangiocarcinoma, C-X-C motif chemokine ligand 9, Interferon-γ, Prognosis

Song Xue, Xi Zihan, Li Ting, et al. Clinical implication of serum CXCL9 and IFN-γ levels in patients with intrahepatic cholangiocarcinoma[J]. Journal of Practical Hepatology, 2021, 24(5): 741-744.

References

[1]秦胜利, 董妍, 孙艺. 肝内胆管癌患者术后预后研究. 实用肝脏病杂志, 2018, 21(4):643-644.
[2]Hamaoka M, Kozaka K, Matsui O, et al. Early detection of intrahepatic cholangiocarcinoma. Jpn J Radiol, 2019, 37(10):669-684.
[3]El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am, 2019, 28(4):587-599.
[4]Lin Y, Li B, Yang X, et al. Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment. Neoplasia, 2019, 21(12):1133-1142.
[5]Tan S, Wang K, Sun F, et al. CXCL9 promotes prostate cancer progression through inhibition of cytokines from T cells. Mol Med Rep, 2018, 18(2):1305-1310.
[6]谭剑, 杨星萍, 田仁江,等. 肺腺癌中T细胞免疫球蛋白黏蛋白分子3与干扰素γ表达及其临床意义. 中华生物医学工程杂志, 2020, 26(3):231-236.
[7]Weber SM, Ribero D, O'Reilly EM, et al. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB, 2015, 18(2):17(8):669-680.
[8]Lendoire JC, Gil L, Imventarza O. Intrahepatic cholangiocarcinoma surgery: the impact of lymphadenectomy. Chin Clin Oncol, 2018, 7(5):53-60.
[9]Sarcognato S, Gringeri E, Fassan M, et al. Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma. Virchows Arch, 2019, 474(1):29-37.
[10] Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology, 2019, 69(4):1803-1815.
[11] 张晓辉, 马莉, 朴颖哲,等. 趋化因子及其受体在胶质瘤中作用的研究进展. 山东医药, 2019, 59(29):89-92.
[12] Bikfalvi A, Billottet C. The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment. Am J Physiol Cell Physiol, 2020, 318(3):542-554.
[13] Nazari A, Ahmadi Z, Hassanshahi G, et al. Effective treatments for bladder cancer affecting CXCL9/CXCL10/CXCL11/CXCR3 axis: a review. Oman Med J, 2020, 35(2):103-110.
[14] Neo SY, Lundqvist A. The multifaceted roles of CXCL9 within the tumor microenvironment. Adv Exp Med Biol, 2020, 1231(4):45-51.
[15] Humblin E, Kamphorst AO. CXCR3-CXCL9: it's all in the tumor. Immunity, 2019, 50(6):1347-1349.
[16] Razis E, Kalogeras KT, Kotsantis I, et al. The role of CXCL13 and CXCL9 in early breast cancer. Clin Breast Cancer, 2020, 20(1):36-53.
[17] Gao HF, Cheng CS, Tang J, et al. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Aging, 2020, 12(1):502-517.
[18] Fukuda Y, Asaoka T, Eguchi H, et al. Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma. Cancer Sci, 2020, 111(2):323-333.
[19] Gao Y, Yang J, Cai Y, et al. IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J Cancer 2018, 143(4):931-943.
[20] Li N, Wang J, Zhang N, et al. Cross-talk between TNF-a and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells. Cancer Immunol Immunother, 2018, 67(2):271-283.
[21] Glasner A, Levi A, Enk J, et al. NKp46 Receptor-mediated interferon-γ production by natural killer cells increases fibronectin 1 to alter tumor architecture and control metastasis. Immunity, 2018, 48(1):107-119.
[22] Zhao H, Dong N, Liu T, et al. Clinical significance of serum type III interferons in patients with gastric cancer. J Interferon Cytokine Res, 2019, 39(3):155-163.
[23] Cao J, Zhang C, Jiang GQ, et al. Expression of GLS1 in intrahepatic cholangiocarcinoma and its clinical significance. Mol Med Rep, 2019, 20(2):1915-1924.

Clinical implication of serum CXCL9 and IFN-γ levels in patients with intrahepatic cholangiocarcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Hua Qi, Chen Qi, You Lan. Clinical feature of 142 patients with anti-tuberculosis agents-induced DILI [J]. Journal of Practical Hepatology, 2021, 24(6): 843-846.
[2]	Liu Jiqing, Yu Guoying, Yang Shengsen, et al. Short-term prognosis of patients with acute on chronic liver failure and invasive fungal infection by four prognostic scoring systems [J]. Journal of Practical Hepatology, 2021, 24(6): 851-854.
[3]	Wu Huijuan, He Nian'an, Xie Li, et al. Contrast-enhanced ultrasonography and serum CA19-9 levels in differential diagnosis of patients with intrahepatic cholangiocellular carcinoma and hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(6): 903-906.
[4]	Guan Haiyan, Yang Wenbin. Clinical features and prognosis of patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2021, 24(5): 713-716.
[5]	Huang Shuangxiang, Yao Chaoguang, Lan Jing, et al. Clinical significance of serum autophagy-related proteins in patients with hepatitis B virus-induced acute on chronic liver failure [J]. Journal of Practical Hepatology, 2021, 24(5): 721-724.
[6]	Li Bianli, Xu Lihong. Differential diagnosis of drug-induced liver injury, drug-induced autoimmune hepatitis and autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(4): 460-463.
[7]	Lu Xiaolong, Xie Chunbao. Implication of IL-6 gene polymorphism in short-term prognosis of patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2021, 24(4): 516-519.
[8]	Zhang Bing, Chen Ruihong, Yang Wei, et al. Application of serum HSP90α and PIVKA-II levels in prognosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(4): 548-551.
[9]	Wang Tingting, Xin Yang, Wang Nana. Expression of CBX7 and PERK incancerous tissues in patients with hepatocellular carcinoma and its implication of prognosis after hepatectomy [J]. Journal of Practical Hepatology, 2021, 24(4): 552-555.
[10]	Yu Zhe, Luo Jing, Yang Yongping. Peripheral blood mononuclear cell GPSM2 levels might be a new marker for prognosis of patients with hepatocellular carcinoma stage III [J]. Journal of Practical Hepatology, 2021, 24(4): 556-560.
[11]	Yu Tao, Li Kuiwu, Yao Lin, et al. Implication of ubiquitinase E2T expression in cancerous tissues in patients with gallbladder cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 593-596.
[12]	Wang Mengyu, Yang Ruixu, Fan Jiangao. Clinical feature and outcomes of patients with metabolic associated fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(3): 308-311.
[13]	Chen Chen, Wang Lianfa, Wang Yan, et al. Serum liver and kidney function tests and myocardial enzymes in 112 patients with coronavirus-19 pneumonia [J]. Journal of Practical Hepatology, 2021, 24(3): 351-354.
[14]	Liu Songtao, Meng Qinghua, Lyu Jun, et al. Clinical feature and prognosis of lymphoma patients with chemotherapy-induced liver failure [J]. Journal of Practical Hepatology, 2021, 24(3): 383-386.
[15]	Kong Xuejie, Li Jiang, Li Haotian, et al. Clinical feature and efficacy of different prognostic scoring models in patients with acute-on-chronic liver failure with different underlying liver diseases [J]. Journal of Practical Hepatology, 2021, 24(3): 387-390.